ROIV 240517 15.00C (ROIV240517C15000) Stock Options, News & Quotes

US OptionsDetailed Quotes

ROIV240517C15000

Watchlist

0.07
0.000.00%

15min DelayTrading Apr 5 15:17 ET

0.00High0.00Low

Intraday

News

Institutional Investors Are Roivant Sciences Ltd.'s (NASDAQ:ROIV) Biggest Bettors and Were Rewarded After Last Week's US$290m Market Cap Gain
Yahoo FinanceMay 5 08:45 ET
Buy Rating Justified by Roivant Sciences' Strategic Positioning and Promising Drug Pipeline
TipRanksMay 2 02:19 ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
TipRanksApr 26 07:50 ET
Express News | Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
BenzingaApr 25 08:08 ET
Express News | Roivant Sciences Ltd - Topline Results Are Expected by End of Calendar Year 2024
ReutersApr 25 08:03 ET
Express News | Roivant and Kinevant Sciences Complete Enrollment in Resolve-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
ReutersApr 25 08:03 ET

Comments

Movers and Shakers

Apr 2 07:16

ColumnsToday's Morning Movers and Top Ratings: DIS, DASH, CVS, GE and More

Morning Movers
Gapping up
$DoorDash(DASH.US)$ stock rose 0.4% after CFRA Research upgraded its investment stance on the food delivery platform to buy from hold, citing its high growth potential.
$Roivant Sciences(ROIV.US)$ stock rose 7.2% after the biotech said its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study.
Gapping down
$NIO Inc(NIO.US)$ fell ...

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer(PFE.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...

Moomoo AI

Jan 5 04:55

The sale of Roivant Sciences shares by an insider, without any recent insider buying, and a high insider ownership can signal mixed sentiments towards the company's future prospects. It could perpetuate caution among potential investors.

Have Roivant Sciences Insiders Been Selling Stock?

Meltyy

Jan 3 06:11

Upcoming Ph 2 readouts in Q1 2024…

$Cellectar BioSciences(CLRB.US)$ Phase 2
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...

70794700

Oct 25, 2023 08:47

$Roivant Sciences(ROIV.US)$ extremely undervalued, by at least 60%? Roivant stock was already priced at ~ $7 with a market cap of $5 Billion when it licensed RVT-3101 from Pfizer for $45 million back in Dec, 2022. Now Roivant just pocketed $5 billion from selling it to Roche, so its stock price shall at least raise to $14 to justify the huge gain only from the Roche deal by simple math, that's probably also why its average analyst price target is about $16.